MNPR (Monopar Therapeutics) Short Percentage of Float


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $89.10
! 2 Warning Signs
View Full Analysis

What is Monopar Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MNPR vs IPSC, ADCT, CMPX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Monopar Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monopar Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Monopar Therapeutics's Short Percentage of Float falls into.


MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Business Description

Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.10
Price